GNRH1 and endometrial cancer: Along these lines, the GnRH agonist DLys6-GnRH, conjugated via a covalent bond with doxorubicin (Zoptarelin doxorubicin or AEZS-108 or AN-152), was proven to exhibit high binding affinity when tested in human breast, ovarian and endometrial cancer cells [52,53,54,55].